Department of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, UK.
Aliment Pharmacol Ther. 2010 Apr;31(7):679-92. doi: 10.1111/j.1365-2036.2010.04230.x.
Non-alcoholic fatty liver disease affects 10-35% of the adult population worldwide; there is no consensus on its treatment. Omega-3 fatty acids have proven benefits for hyperlipidaemia and cardiovascular disease, and have recently been suggested as a treatment for non-alcoholic fatty liver disease.
To review the evidence base for omega-3 fatty acids in non-alcoholic fatty liver disease and critically appraise the literature relating to human trials.
A Medline and PubMed search was performed to identify relevant literature using search terms 'omega-3', 'N-3 PUFA', 'eicosapentaenoic acid', 'docosahexaenoic acid', 'non-alcoholic fatty liver disease' and 'NAFLD'.
Omega-3 fatty acids are important regulators of hepatic gene transcription. Animal studies demonstrate that they reduce hepatic steatosis, improve insulin sensitivity and reduce markers of inflammation. Clinical trials in human subjects generally confirm these findings, but have significant design inadequacies.
Omega-3 fatty acids are a promising treatment for non-alcoholic fatty liver disease which require to be tested in randomized placebo-controlled trials.
非酒精性脂肪性肝病影响全球 10-35%的成年人；其治疗方法尚无共识。ω-3 脂肪酸已被证明对高脂血症和心血管疾病有益，最近被提议作为非酒精性脂肪性肝病的治疗方法。
综述 ω-3 脂肪酸在非酒精性脂肪性肝病中的证据基础，并批判性评价与人体试验相关的文献。
使用“omega-3”、“N-3 PUFA”、“二十碳五烯酸”、“二十二碳六烯酸”、“非酒精性脂肪性肝病”和“NAFLD”等搜索词，在 Medline 和 PubMed 上进行搜索，以确定相关文献。
ω-3 脂肪酸是肝基因转录的重要调节剂。动物研究表明，它们可减少肝脂肪变性、改善胰岛素敏感性并降低炎症标志物。人体临床试验通常证实了这些发现，但设计存在明显不足。
ω-3 脂肪酸是一种有前途的非酒精性脂肪性肝病治疗方法，需要在随机安慰剂对照试验中进行测试。
